English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
| Clinical Publications | Scientific Publications |
| December 2018 | |
| Imatinib is still recommended for frontline therapy for CML (Hantel A et al. Blood Adv, December 2018Blood Adv, December 2018) |
A kinase profile-adapted drug combination elicits cooperative effects on leukemia cells carryging BCR-ABL1T315l in PH+ CML (Gleixner KV et al. Leuk Res, December 2018) (epub ahead of print) |
| Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review (Cortes JE et al. J Hematol Oncol, December 2018) |
Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations |
| A second-generation TKI should always be used as initial therapy for CML (Cortes JE. Blood Adv, December 2018) |
Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia (Bidet A et al. Haematologica, December 2018) (epub ahead of print) |
| Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV (Michel C et al. Haematologica, December 2018) (epub ahead of print) |
|
|
Nilotinib in the treatment of chronic myeloid leukemia |
|
|
Cardiovascular risk and cardiovascular events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors |
|
| November 2018 | |
| Molecular monitoring in CML: how deep? How often? How should it influence therapy? (Shanmuganathan N et al. Blood, November 2018) |
A modified DAW-22 compound F-B1 inhibits BCR-ABL and induces apoptosis in chronic myelogenous leukemia cells (Wang F et al. Anticancer Drugs, November 2018) (epub ahead of print) |
| Treatment-free remission with first- and second-generation tyrosine kinase inhibitors (Cortes J et al. Am J Hematol, November 2018) |
Genomic amplification of BCR-ABL1 fusion gene and its impact of the disease progression mechanism in patients with chronic myelogenous leukemia (Chandran RK et al. Gene, November 2018) (epub ahead of print) |
| The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study (Di Felice E et al. BMC Cancer, November 2018) |
To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia (Schiffer JT et al. Haematologica, November 2018) |
| Back to the future: TFR and pregnancy in CML (Abruzzese E et al. Eur J Haematol, November 2018) (epub ahead of print) |
A new BCR-ABL1 Drosophilia model as a powerful tool to elucidate pathogenesis and progression of chronic myeloid leukemia (Bernardoni R et al. Haematologica, November 2018) (epub ahead of print) |
|
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients (García-Gutiérrez V et al. Ann Hematol, November 2018)(epub ahead of print) |
Epigenetic regulation of HOTAIR in advanced chronic myeloid leukemia (Li Z et al. Cancer Manag Res, November 2018) |
| Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia (Klil-Drori AJ et al. Cancer, November 2018) (epub ahead of print) |
Chronic myeloid leukemia with complex karyothypes: Prognosis and therapeutic approaches (Asnafi AA et al. J Cell Physiol, November 2018) (epub ahead of print) |
| October 2018 | |
| Treatment-free remission after second-line nilotinib treatment (Mahon MX et al. Ann Intern Med, October 2018) |
Modeling ponatinib resistance in tyrosine kinase inhibitor naïve and dasatinib resistant BCR-ABL1+ cell lines (Lu L et al. Oncotarget, October 2018) |
| Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells (Ross DM et al. Leukemia, October, 2018) (epub ahead of print) |
A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease (Sweet K et al. Leuk Res, October 2018) (epub ahead of print) |
| Adult leukemia survival trends in the United States by subtype: A population-based registry study of 370,994 patients during 1995-2009 (Bailey C et al. Cancer, October 2018) (epub ahead of print) |
Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value (Hidalgo-López JE et al. Cancer, October 2018) (epub ahead of print) |
| Early molecular response ≤ 1% has strong prognostic impact for CML patients that switch to second line therapy with BCR-ABL ≤ 10% and no major molecular response (Bonecker S et al. Br J Haematol, October 2018) (epub ahead of print) |
Alteration of cellular and immune-related properties of bone marrow mesenchymal stem cells and macrophages by K562 chronic myeloid leukemia cell derived exosomes (Jafarzadeh N et al. J Cell Physiol, October 2018) (epub ahead of print) |
| A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors (Zulbaran-Rojas A et al. Cancer Med, October 2018) (epub ahead of print) |
Optimized digital droplet PCR for BCR-ABL (Maier J et al. J Mol Diagn, October 2018) (epub ahead of print) |
| Treatment-free remission in patients with chronic myeloid leukemia (Rea D et al. Int J Hematol, October 2018) |
Clinical evaluation of massively parallel RNA sequencing for detecting recurrent gene fusion in hematologic malignancies (Kim B et al. J Mol Diagn, October 2018) (epub ahead of print) |
| Tyrosine kinase inhibitor interruptions, discontinuation and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY (Hehlmann R et al. Ann J Hematol, October 2018) (epub ahead of print) |
Real-time qualitative PCR: a reliable molecular diagnostic and follow-up tool for ‘minimal residual disease’ assessment in chronic myeloid leukemia (Azad NA et al. Biosci Rep, October 2018) |
|
|
Searching for potential novel BCR-ABL tyrosine kinase inhibitors through G-QSAR and docking studies of some novel 2-phenazinamine derivates |
|
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia |
|
| September 2018 | |
| Chronic myeloid leukemia relapsing 25 years after allogeneic stem cell transplantation (Reikvam H et al. Case Rep Hematol, September 2018) |
Ponatinib activates an inflammatory response in endothelial cells via ERK5 SUMOylation (Paez-Mayorga J et al. Front Cardiovasc Med, September 2018) |
| Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: The PEARL observational study (Heiblig M et al. Exp Hematol, September 2018) (epub ahead of print) |
Autophagy and mitochondrial metabolism: Insights into their role and therapeutic potential for chronic myeloid leukaemia (Baquero J et al. FEBS J, September 2018) (epub ahead of print) |
| Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib (Ottmann O et al. Blood Cancer J, September 2018) |
Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal (Toofan P et al. Cell Death Dis, September 2018) |
| Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase era (Savoie ML. Leuk Res, September 2018) (epub ahead of print) |
Systematic review of pre-clinical chronic myeloid leukemia |
| Identifying tyrosine kinase inhibitor nonadherence in chronic myeloid leukemia: subanalysis of TAKE-IT pilot study (Clin Lymphoma Myeloma Leuk, September 2018) |
CircBA9.3 supports the survival of leukaemic cells by up-regulating C-ABL1 or BCR-ABL1 protein levels (Pan Y et al. Blood Cells Mol Dis, September 2018) (epub ahead of print) |
| Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology (Radich JP et al. J Natl. Compr Canc Netw, September 2018) |
Hydroxycoumarin OT-55 kills CML cells alone or in synergy with imatinib or Synribo: involvement of ER stress and DAMP release (Mazumder A et al. Cancer Lett, September 2018) (epub ahead of print) |
| Gene expression analysis of noncoding PCA3 gene in patients with chronic myeloid leukemia (Sajjadi E et al. J Cancer Res Ther, July-September 2018) |
|
| August 2018 | |
| Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib (Nicolini FE et al. Exp Hematol, August 2018) |
Development, function and clinical significance of plasmacytoid dentritic cells in chronic myeloid leukemia (Inselmann S et al. Cancer Res, August 2018) (epub ahead of print) |
| Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia (Hughes TH et al. Haematologica, August 2018) (epub ahead of print) |
Consensus of BCR-ABL-1 reporting in chronic myeloid leukemia in the UK (Cross NCP et al. Br J Haematol, August 2018) (epub ahead of print) |
| Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States (Jabbour EJ et al, August 2018) (epub ahead of print) |
The clinical outcomes of chronic myeloid leukemia patients harboring alternatively spliced BCR-ABL variants (Ishida T et al. Hematology, August 2018) (epub ahead of print) |
| Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison (Glauche I et al. Sci Rep, August 2018) |
Evaluation of resistance to HIV-1 infection ex vivo of PBNCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors (Bermejo M et al. Biochem Pharmacol, August 2018) (epub ahead of print) |
| Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic-phase; the DASPERSE study (Kim DW et al. Ann Hematol, August 2018) |
Crosstalk between BCR-ABL and protease-activated receptor1 (PAR1) suggests a novel target in chronic myeloid leukemia |
| Imatinib through levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia (Natarajan H et al. Leuk Lymphoma, August 2018) (epub ahead of print) |
Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL-1 |
| July 2018 | |
| Comparison of frequency and sensitivity of BCR-ABL1 kinase domain mutations in Asian and white patients with imatinib-resistant chronic-phase chronic myeloid leukemia (Kim H et al. Clin Lymphoma Myeloma Leuk, July 2018) (epub ahead of print) |
Single-molecule sequencing reveals patterns of pre-existing drug resistance that suggest treatment strategies in Philadelphia-positive leukemias (Schmitt MW et al. Clin Cancer Res, July 2018) (epub ahead of print) |
| Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: a case report and literature review (Park E et al. Ann Hematol, July 2018) (epub ahead of print) |
Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy |
| Chronic myeloid leukemia and pregnancy: patient and partner perspectives (Luskin MR et al. Expert Rev Hematol, July 2018) (epub ahead of print) |
BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia (Pagani IS et al. Haematologica, July 2018) (epub ahead of print) |
| Switches of tyrosine-kinase inhibitors in chronic phase of chronic myeloid leukemia in real life (Am J Hematol, July 2018) (epub ahead of print) |
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high risk disease (Branford S et al. Blood, July 2018) (epub ahead of print) |
| Extended dose with CC-486 (oral azacitidine) in patients with myloid malignancies (Savona MR et al. Am J Hematol, July 2018) (epub ahead of print) |
Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia (Bouillon AS et al. Blood Adv, July 2018) |
|
|
A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML (Gopal S et al. Blood Adv, July 2018) |
| The underestimated role of basophils in PH+ CML (Valent P et al. Eur J Clin Invest, July 2018) |
|
| HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of has-miR-196a targeting BCR/ABL1 (Bamodu OA et al. Exp Cell Res, July 2018) (epub ahead of print) |
|
| CDA gene silencing regulated the proliferation and apoptosis of chronic myeloid leukemia K562 cells (Wei XF et al. Cancer Cell Int, July 2018) |
|
| The potential of exosomes derived from chronic myelogenous leukemia cells as a biomarker (Kang KW et al. Anticancer Res, July 2018) |
|
| June 2018 | |
| Effect of adherence-enhancing interventions on adherence to tyrosine kinase inhibitor treatment in chronic myeloid leukemia (TAKE-IT): A quasi-experimental pre-post intervention multicenter pilot study (Leader A et al. Clin Lymphoma Myeloma Leuk, June 2018) (epub ahead of print) |
Past, present, and future of BCR-ABL inhibitors: from chemical development to clinical efficacy (Rossari F et al. J Hematol Oncol, June 2018) (Epub ahead of print) |
| The story of tyrosine kinase inhibitors discontinuation in clinical practice (Rousselot P. Leuk Lyphoma, June 2018) (epub ahead of print) |
Novel combined Ato-C treatment synergistically suppresses proliferation of BCR-ABL-positive leukemic cells in vitro and in vivo |
| Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: the younger, the later, the worse? (Latagliata R et al. Eur J Haematol, June 2018) |
Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML (Brück O et al. Leukemia, June 2018) (epub ahead of print) |
| Upfront low-dose ponatinib (15mg/day) for multi-TKI resistant chronic myeloid leukemia (Tefferi A et al. Hematol Oncol, June 2018) |
Integrated computational biology analysis to evaluate target genes for chronic myelogenous leukemia (Zheng Y et al. Mol Med Rep, June 2018) (epub ahead of print) |
|
Present results and future perspectives in optimizing chronic myeloid leukemia therapy |
Chronic myelogenous leukemia on target (Némethová V et al. Cancer Med, June 2018) (epub ahead of print) |
|
Beyond maximum grade: modernizing the assessment and reporting of adverse events in haematological malignancies |
SiRNA/Lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo (Valencia-Serna J et al. Eur J Pharm Biopharm, June 2018) (epub ahead of print) |
|
Comparative analysis of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic myeloid leukemia following sub-optimal response to first-line imatinib |
|
| May 2018 | |
| Management of pregnancy in women with chronic myeloid leukemia (Ross D et al. J Clin Oncol, May 2018) (epub ahead of print) |
Experimental and integrative analyses identify an ETS1 network downstream BCR-ABL in chronic myeloid leukemia (CML) (Desterke C et al. Exp Hematol, May 2018) (epub ahead of print) |
| The evolution of dasatinib dosage over the years and its relevance to other anticancer medications (Schiffer CA et al. Cancer, May 2018) (epub ahead of print) |
Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission (Bocchia M et al. Front Oncol, May 2018) |
|
Long-term follow-up of de novo chronic myelogenous leukemia patients on imatinib first-line |
Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition (Mitchell R et al. J Natl Cancer Inst, May 2018) |
| Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia (Naqvi K et al. Cancer, May 2018) (epub ahead of print) |
Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells (Gover-Proaktor A et al. Leuk Lymphoma, May 2018) (epub ahead of print) |
| Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicenter, non-randomised trial (Saussele S et al. Lancet Oncology, May 2018) (epub ahead of print) |
Targeting HSP90 dimerization via the C-terminus is effective in imatinib resistant CML and lacks heat shock response (Bhatia S et al. Blood, May 2018) (epub ahead of print) |
| Reduced-dose imatinib in chronic-phase CML (Das M et al. Lancet Oncol, May 2018) (epub ahead of print) |
|
|
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study |
|
|
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French chronic myeloid leukemia study group |
|
|
Pregnancy in patients with chronic myeloid leukemia |
|
|
Real-life experience with ponatinib in chronic myeloid leukemia: A multicenter observational study |
|
|
Breastfeeding in patients with chronic myeloid leukemia: Case series with measurements of drug concentrations in maternal milk and literature review |
|
| April 2018 | |
| Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia (Atallah E et al. BMC Cancer, April 2018) |
Validation of the EUTOS long-term survival score in a recent independent cohort of “real-world” CML patients (Geelen IGP et al. Leukemia, April 2018) |
|
Considerations of treatment-free remission in patients with chronic myeloid leukemia: A joint patient-physician perspective |
The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia (Spiess B et al. PLoS One, April 2018) |
|
Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic phase chronic myeloid leukemia |
Evaluation of the primitive fraction by functional in vitro assays at the RNA and DNA level represents a novel tool for complementing molecular monitoring in chronic myeloid leukemia (Ruiz MS et al. Oncotarget, April 2018) |
|
Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia |
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients (Ricciardi MR et al. Oncotarget, April 2018) |
|
Ponatinib as second-line treatment in chronic-phase chronic myeloid leukemia patients in real-life practice |
Droplet digital PCR for BCR-ABL (P210) detecting of CML: A high sensitive method of the minimal residual disease and disease progression (Wang WJ et al. Eur J Haematol, April 2018) (epub ahead of print) |
| Aberrant DNA methylation of SOCS1 gene is not associated with resistance to imatinib mesylate among chronic myeloid leukemia patients (Elias MH et al. Cardiovasc Hematol Disord Drug Targets, April 2018) (epub ahead of print) |
|
| CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells (Huang SY et al. J Cell Physiol, April 2018) |
|
|
Wool-like hollow polymeric nanoparticles for CML chemo-combinatorial therapy |
|
| New rapid method to detect BCR-ABL fusion genes with multiplex RT-qPCR in one-tube at a time (Tong YQ et al. Leuk Res, April 2018) (epub ahead of print) |
|
| March 2018 | |
| Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial (Cortes JE et al. Blood, March 2018) (epub ahead of print) |
|
| Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib (Efficace F et al. Cancer, March 2018) (epub ahead of print) |
Bone marrow niche trafficking of MiR-126 controls the self-renewal of leukemia cells in chronic myelogenous leukemia (Zhang B et al. Nat Med, March 2018) (epub ahead of print) |
| Prediction of sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase (Sasaki K et al. Cancer, March 2018) |
Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy (Eadie LN et al. Leukemia, March 2018) (epub ahead of print) |
|
Safety and efficacy of nilotonib in routine clinical practice with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study |
Plasma and intracellular concentrations in an elderly patient with chronic myeloid leukemia receiving low-dose dasatinib therapy (Imamura M et al. Geriatr Gerontol Int, March 2018) |
|
Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report |
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemic cells (Mathew NR et al. Nat Med, March 2018) |
|
Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy |
Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor |
|
When to stop tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia |
|
|
Current information and recommendations on the discontinuation of TKI inhibitors in chronic myeloid leukemia |
|
| February 2018 | |
| Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV (Saussele S et al. Leukemia, February 2018) (epub ahead of print) |
|
|
Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic-myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the IIIb ENESTswift study |
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations |
|
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study |
Effect of ABCG2, OCT1, and AB1 (MDR1) gene expression on treatment-free remission in a EURO-SKI subtrial (Rinaldetti S et al. Clin Lymphoma Myeloma Leuk, February 2018) (epub ahead of print) |
|
The cure of chronic myeloid leukemia: Are we there yet? |
Overexpression of TpK2 is linked to imatinib resistance and activation of MEK-ERK and NF-kB pathways in a model of chronic myeloid leukemia (Chorzalska A et al. Mol Oncol, February 2018) |
| Considerations for successful treatment-free remission in chronic myeloid leukemia (Goldberg SL et al. Clin Lymphoma Myeloma Leuk, February 2018) |
Therapy-free remission in chronic myeloid leukemia: possible mechanisms (Gale RP et al. Expert Rev Hematol, February 2018) |
| Chronic myelogenous leukemia: Pregnancy in the era of stopping tyrosine kinase inhibitor therapy (Berman E et al. J Clin Oncol, February 2018) (epub ahead of print) |
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy (Soverini S et al. Mol Cancer, February 2018) |
| Identification of chronic myeloid leukemia patients treated with imatinib who are potentially eligible for treatment discontinuation by assessing real-life molecular response on the international scale in a EUTOS-certified lab (Heinrichs A et al. Leuk Res, February 2018) (epub ahead of print) |
Has-mir183/EGF-1 mediated regulation of E2F1 is required for CML stem/progenitor cell survival (Pellicano F et al. Blood, February 2018) (epub ahead of print) |
|
An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States |
Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia |
|
Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing |
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia |
|
Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase |
Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis
(Cargnin S et al. Pharmacol Res, February 2018) |
|
Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chroni myeloid leukemia |
|
| January 2018 | |
| Dasatinib dose management for the treatment of chronic myeloid leukemia (Talpaz M et al. Cancer, January 2018) (epub ahead of print) |
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors (Alhuraiji A et al. Am J Hematol, January 2018) |
| Dasatinib-induced pulmonary arterial hypertension – A rare late complication (Ibrahim U et al. J Oncol Pharm Pract, January 2018) (epub ahead of print) |
Monitoring of leukemia stem cells in chronic myeloid leukemia patients (Cui J et al. Leuk Lymphoma, January 2018) (epub ahead of print) |
|
Dasatinib-induced pulmonary arterial hypertension |
Altered intracellular signaling by imatinb increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells (Hirao T et al. Cancer Sci, January 2018) |
|
Will tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future? |
Lithium, a classic drug in psychiatry, improves nilotinib-mediated antileukemic effects |
| Monitoring TKI therapeutic responses with the panel of metabolic biomarkers in the chronic myeloid leukemia patients (Yang B et al. Cancer Sci, January 2018) (epub ahead of print) |
Dual drug targeting of mutant BCR-ABL induces inactive confirmation: |
|
Racial differences in four leukemia subtypes: Comprehensive descriptive epidemiology |
|
|
Antitumor effects of blocking protein neddylation in T3151-BCR-ABL leukemia cells and leukemia stem cells |
|
|
Blockage of endoplasmic reticulum attenuates nilotinib-induces cardiotoxicity by inhibition of the Akt-GSK3ß-Nox4 signaling |
|
|
Effects on antioxidants on apoptosis induced by dasatinib and nilotinib in K562 cells |
|
| Therapeutic targeting of CK2 in acute and chronic leukemias (Buontempo F et al. Leukemia, January 2018) |
|
| December 2017 | |
| Treatment-free remission in CML: who, how, and why? (Mahon FX. Hematology Am Soc Hematol Educ Program, December 2017) |
Exosomes derived from imatinib-resistant chronic myeloid leukemia cells mediate a horizontal transfer of drug-resistant trait by delivering miR-365 (Min QH et al. Exp Cell Res, December 2017) (epub ahead of print) |
| Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy (Barber MC et al. Hematology Am Soc Hematol Educ Program, December 2017) |
Ecotopic viral integration site 1 (EVL1) transcriptionally targets talin 1 (TLN1) and upregulates its expression in chronic myeloid leukemia (Halder A et al. Leuk Lymphoma, December 2017) (epub ahead of print) |
| Novel approaches to therapy in CML (Bhatia R et al. Hematology Am Soc Hematol Educ Program, December 2017) |
C1206, a novel curcumin derivate, potently inhibits Hsp90 and human chronic myeloid leukemia cells in vitro (Fan YL et al. Acta Pharmacol, December 2017) (epub ahead of print) |
| Front-line treatment options for chronic-phase chronic myeloid leukemia (Shah NP et al. J Clin Oncol, December 2017) (epub ahead of print) |
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib (Giallongo C et al. J Cell Mol Med, December 2017) (epub ahead of print) |
| Mechanisms of resistance to targeted therapies in chronic myeloid leukemia (Lussana F et al. Handb Exp Pharmacol, December 2017) (epub ahead of print) |
Controversies regarding use of myeloid growth factors in leukemia (Poston JN et al. J Natl Compr Canc Netw, December 2017) |
| Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapharesis appropriate? A case report and review of the literature (Staley EM et al. Transfusion, December 2017) (epub ahead of print) |
|
|
Atypcial chronic myeloid leukemia: a rare entity with management challenges (Dhakal P et al. Future Oncol, December 2017)(epub ahead of print) |
|
|
Successful ovarian stimulation for fertility preservation in a patient with chronic myeloid leukemia: switch from nilotinib to interferon-alpha |
|
CML Publications 2014-2017
Access 2017 CML publications here
Access 2016 CML publications here
Access 2015 CML publications here
Access 2014 CML publications here
Would you like to suggest an interesting paper or article? >> Please provide us with the details here and we will be happy to review your suggestion!
Search for more publications on CML at PubMed.gov
